This technical dossier outlines the molecular structure, binding affinity, and analytical standards of the 20mg CJC-1295 research vial (Modified GRF 1-29). Designed strictly for laboratory research use, CJC-1295 serves as a core model peptide for evaluating growth hormone axis kinetics in preclinical research.
This technical dossier outlines the molecular structure, binding affinity, and analytical standards of the 20mg CJC-1295 research vial (Modified GRF 1-29). Designed strictly for laboratory research use, CJC-1295 serves as a core model peptide for evaluating growth hormone axis kinetics in preclinical research.
A CJC-1295 research vial contains high-purity, lyophilized CJC-1295 without Drug Affinity Complex (Modified GRF 1-29), a synthetic 29-amino-acid growth-hormone-releasing hormone (GHRH) analog. In preclinical models, it binds selectively to pituitary GHRH receptors to stimulate pulsatile growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) expression for tissue repair and metabolic research.
When purchasing a cjc-1295 research vial, research institutions require consistent chemical integrity and clear analytical documentation. Unlike extended-release variants, CJC-1295 without DAC mirrors natural physiological GHRH pulsing by exhibiting a brief half-life in vitro and in vivo. This precise pharmacokinetic control makes the 20mg vial a staple reagent across endocrinology and cellular signaling studies.
CJC-1295 No DAC is a truncated synthetic peptide modeled on the first 29 amino acids of endogenous human GHRH (GHRH 1-29). Native GHRH 1-29 is rapidly cleaved by the enzyme dipeptidyl peptidase-IV (DPP-IV) in plasma, restricting its functional half-life to under ten minutes in preclinical models. To overcome metabolic instability, CJC-1295 incorporates four strategic amino acid substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27.
These specific residue modifications render the molecule highly resistant to enzymatic cleavage by DPP-IV while preserving high binding affinity for the pituitary GHRH receptor. In vitro receptor binding assays demonstrate that modified GRF 1-29 maintains full agonist activity, initiating adenylate cyclase activation and cyclic adenosine monophosphate (cAMP) accumulation within pituitary somatotropes. As a targeted GHRH analog, it provides investigators with a reliable mechanism for evaluating physiological GH output without inducing non-specific receptor crosstalk.
Preclinical studies suggest that CJC-1295 activates the growth hormone axis by mimicking endogenous peptide signal cascades. Upon binding to GHRH receptors, the intracellular cAMP pathway triggers the release of pre-synthesized growth hormone from somatotropes, followed by transcription of new GH mRNA. In animal models, administration of CJC-1295 produces a sharp, transient spike in serum GH concentration, closely simulating the natural pulsatile profile observed under baseline conditions.
Downstream of pituitary activation, systemic growth hormone signals hepatic tissue to synthesize and secrete insulin-like growth factor 1 (IGF-1). Researchers investigating muscle protein synthesis, cartilage extracellular matrix deposition, and lipid oxidation rely on this cascade. Preclinical data indicate that sustained exposure to pulsatile GHRH analogs elevates baseline IGF-1 markers over multi-week experimental protocols, providing valuable insights into cellular turnover and tissue regeneration models within growth hormone secretagogues literature.
Reliable experimental outcomes require absolute chemical purity and batch consistency. Every 20mg cjc-1295 research vial supplied by PX1 Research undergoes stringent multi-stage testing within ISO 17025 accredited analytical laboratories. We employ Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity levels exceeding 98.0%, ensuring the absence of truncated sequences or synthesis side-products.
In addition to purity profiles, sequence identity is confirmed via Liquid Chromatography-Mass Spectrometry (LC-MS) matrix validation. To protect sensitive cell culture protocols and prevent inflammatory artifact interference in animal models, each lot is subjected to chromogenic LAL assays to confirm endotoxin levels remain strictly below <0.5 EU/mg. All products are USA-manufactured in GMP-compliant facilities and shipped directly from our primary distribution hubs in California and Arizona with same-day dispatch for orders finalized Monday through Friday before cutoff.
Selecting the correct secretagogue for laboratory protocols depends heavily on desired half-life and receptor specificity. The unmodified CJC-1295 No DAC 20mg features an approximate half-life of 30 minutes in preclinical models, allowing researchers to study natural physiological GH release spikes. Conversely, CJC-1295 with DAC 5mg includes a Lysine-linker and Drug Affinity Complex that covalently binds to plasma albumin, extending the terminal half-life to several days and producing continuous, non-pulsatile GH elevation.
When compared to earlier GHRH constructs like Sermorelin 2mg, CJC-1295 No DAC exhibits significantly enhanced enzymatic stability and receptor affinity due to its four-point amino acid substitutions. Additionally, while GHRH analogs act strictly on the GHRH receptor, selective ghrelin receptor agonists such as Ipamorelin 5mg operate through the growth hormone secretagogue receptor (GHSR-1a). Dual-pathway studies frequently utilize combinations of GHRH analogs and GHSR agonists to evaluate synergistic GH release mechanisms in laboratory models.
Lyophilized CJC-1295 requires careful reconstitution to maintain structural integrity prior to assay deployment. Laboratory standard operating procedures dictate working under a laminar flow hood using sterile technique. Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride solution should be introduced down the glass inner wall of the vial to minimize mechanical shear forces on the peptide matrix.
Direct jetting of diluent onto the freeze-dried powder can induce aggregation or denaturation. Gentle swirling without shaking is recommended until the lyophilate is completely dissolved in liquid medium. For precise concentration calculations across varying assay volumes, researchers can reference our interactive peptide reconstitution guide or explore methodological protocols in our dedicated peptide research library.
In its original lyophilized format, a 20mg cjc-1295 research vial exhibits exceptional stability when stored at -20°C or -80°C, remaining viable for up to 24 months. Storage at standard refrigeration temperatures (2°C to 8°C) is acceptable for short-term transit or immediate use within 30–60 days, provided the vial remains sealed away from light exposure.
Following reconstitution, liquid aliquots should be maintained at 2°C to 8°C and utilized within 21 to 28 days if preserved with bacteriostatic agents. For extended experimental timelines requiring unpreserved diluents, immediate single-use sub-aliquoting into sterile polypropylene cryovials is recommended to prevent degradation caused by multiple freeze-thaw cycles.
PX1 Research serves as a premier USA supplier of high-purity research compounds for academic institutions, biotechnology firms, and clinical research laboratories. Every compound batch is backed by lot-specific documentation available directly on our portal, detailing raw sequence verification, mass spectroscopy chromatograms, and endotoxin analysis.
Principal investigators and laboratory managers sourcing reagents at scale can access bulk pricing, customized vial configurations, and dedicated account support through our wholesale laboratory accounts system. Browse our complete catalog of high-purity peptides and reference materials at our all research peptides directory.
What is a cjc-1295 research vial used for in laboratory settings?
A CJC-1295 research vial is used in preclinical laboratory environments to investigate growth hormone releasing hormone (GHRH) receptor signaling, pituitary GH secretion patterns, downstream IGF-1 gene expression, and cellular regeneration kinetics in cell cultures or animal models.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex moiety, resulting in a short half-life (~30 minutes) that simulates natural, pulsatile growth hormone release. CJC-1295 with DAC binds to plasma albumin, extending its biological half-life to several days for continuous GH elevation.
What is the purity level of the CJC-1295 20mg research vial from PX1 Research?
Every CJC-1295 20mg research vial from PX1 Research is verified by RP-HPLC and mass spectrometry to meet or exceed a 98.0% purity threshold, accompanied by a lot-specific Certificate of Analysis.
How should a lyophilized CJC-1295 research vial be stored upon arrival?
Unopened, lyophilized vials should be stored in a freezer at -20°C or -80°C for long-term stability. Short-term storage at refrigerated temperatures (2°C to 8°C) is acceptable away from direct light exposure.
What liquid reconstitutes a CJC-1295 research vial for in vitro protocols?
Researchers typically reconstitute CJC-1295 using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) for multi-use laboratory testing, or sterile 0.9% Sodium Chloride for single-use cell culture assays.
What endotoxin standards apply to PX1 Research CJC-1295 vials?
All CJC-1295 research lots undergo chromogenic LAL endotoxin testing to ensure levels are certified under <0.5 EU/mg, protecting experimental cell assays and animal models from pyrogenic artifacts.
How does CJC-1295 resist enzymatic breakdown compared to native GHRH?
CJC-1295 contains four specific amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that shield the peptide against rapid degradation by dipeptidyl peptidase-IV (DPP-IV), extending its functional availability in experimental models.
Can CJC-1295 No DAC be evaluated in combination with Ghrelin agonists?
Yes, preclinical studies frequently evaluate GHRH analogs like CJC-1295 alongside selective growth hormone secretagogue receptor (GHSR) agonists like Ipamorelin to observe dual-pathway synergistic effects on pituitary GH release.
Where are PX1 Research CJC-1295 vials manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based, GMP-compliant facilities and dispatched same-day (Monday through Friday) from our California and Arizona logistics hubs.
How can institutional laboratories procure CJC-1295 vials in bulk?
Institutional buyers and research facilities can submit procurement applications through our wholesale portal to establish dedicated account management, bulk pricing tiers, and custom lot reservations.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.